Načítá se...
Romosozumab for the treatment of osteoporosis
Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediato...
Uloženo v:
| Vydáno v: | Osteoporos Sarcopenia |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Korean Society of Osteoporosis
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6362945/ https://ncbi.nlm.nih.gov/pubmed/30775535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.afos.2018.03.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|